

FINANCIAL STATEMENTS (Un-Audited)
For the period from 01.07.2017 to 31.12.2017



THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207

Muhtaram Shareholder(s),
Assalamu Alaikum Wa Rahmatullah,

As per rule 13 of Securities and Exchange Rules-1987 and Bangladesh Accounting Standard (BAS) -34, we are pleased to enclose herewith the un-audited Statement of Financial Position as at 31st December 2017, the Statement of Profit or Loss and other Comprehensive Income, Statement of Cash Flows and Statement of Changes in Equity for the half-year ended 31st December, 2017 for your kind perusal.

STATEMENT OF FINANCIAL POSITION (Un-Audited)

As at 31st December, 2017

			Amount in Taka	
Notes	As at 31.12.2017	As at 30.06.2017		
ASSETS:				
Non-Current Assets:				
Property, Plant and Equipment	02	1,163,324,054	1,116,332,498	
Capital work-in-progress	02.1	187,573,672	26,614,186	
Investment in Marketable Securities (AFS)	03	407,624,041	359,107,400	
Investment in associate	03.01	9,123,147	9,123,147	
		735,107,603	643,644,663	
Current Assets :				
Inventories	04	318,806,588	264,194,238	
Accounts Receivable		22,067,371	14,642,851	
Advances, Deposits & Prepayments	05	207,644,333	167,384,398	
Cash & Cash Equivalents	06	186,589,311	197,423,176	
		2,502,752,517	2,154,821,894	
TOTAL ASSETS				
SHAREHOLDERS' EQUITY AND LIABILITIES:				
Shareholders' Equity:				
Share Capital		284,032,980	258,211,800	
Net Gain on Marketable Securities (AFS)	03	333,150,555	289,485,578	
Tax Holiday Reserve		4,392,110	4,392,110	
Retained Earnings	07	631,606,160	552,873,744	
		1,253,181,805	1,104,963,231	
Non-Current Liabilities				
Deferred Tax Liability	08	383,319,367	242,737,392	
	09	89,829,541	80,513,227	
		776,421,804	726,608,044	
Current Liabilities:				
Bank & Other Finance	10	277,490,453	326,811,195	
Accounts and Other Payables	11	498,931,351	399,796,849	
		2,502,752,517	2,154,821,894	
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES				
Net Asset Value (NAV) per Share (restated-30.06.2017)		44.12	38.90	


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Dated, Dhaka
27-Jan-17

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)
For the Half-year ended 31st December, 2017


Amount in Taka				
Notes	For the half-year (July 01, 2017 to December 31, 2017)	For the half-year (July 01, 2016 to December 31, 2016)	For the Quarter (October 01, 2017 to December 31, 2017)	For the Quarter (October 01, 2016 to December 31, 2016)
Revenue	2,469,779,682	1,978,586,249	1,234,368,494	1,045,838,834
Cost of goods sold	(1,467,599,537)	(1,177,512,003)	(733,784,069)	(622,203,150)
Gross Profit	1,002,180,145	801,074,246	500,584,425	423,635,684
Operating Expenses:				
Administrative expenses	(55,058,922)	(46,366,506)	(25,921,798)	(23,350,582)
Selling & Distribution expenses	(706,673,990)	(565,536,172)	(327,209,235)	(272,579,392)
	<u>(761,732,912)</u>	<u>(611,902,678)</u>	<u>(353,131,033)</u>	<u>(295,929,974)</u>
Operating Profit	240,447,233	189,171,568	147,453,392	127,705,710
Financial charges	(17,847,994)	(7,923,834)	(10,338,245)	(5,827,671)
Other income	350,798	2,036,052	300,647	1,712,682
	<u>222,950,037</u>	<u>183,283,786</u>	<u>137,415,794</u>	<u>123,590,721</u>
Workers' P.P. Fund & Welfare Fund	(10,616,668)	(8,727,799)	(6,543,609)	(5,885,272)
Net Profit before tax	212,333,369	174,555,987	130,872,185	117,705,449
Less: Income tax expenses				
Current tax	(47,691,474)	(36,099,747)	(28,068,927)	(22,599,495)
Deferred tax	4,464,651	6,700,069	4,335,739	6,914,346
	<u>(43,226,823)</u>	<u>(29,399,678)</u>	<u>(23,733,188)</u>	<u>(15,685,149)</u>
Net Profit after tax	169,106,546	145,156,309	107,138,997	102,020,300
Other Comprehensive Income:				
Change in fair value of Marketable Securities (AFS)	48,516,641	5,589,616	23,198,231	(14,251,633)
Deferred tax	(4,851,664)	(558,962)	(2,319,823)	1,425,163
Total other comprehensive income for the period, net of tax	<u>43,664,977</u>	<u>5,030,654</u>	<u>20,878,408</u>	<u>(12,826,470)</u>
Total other comprehensive income for the period 31st December, 2017	<u>212,771,523</u>	<u>150,186,963</u>	<u>128,017,405</u>	<u>89,193,830</u>
Earnings per share-basic (restated-2016)	5.95	5.11	3.77	3.59


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
27-Jan-17


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CHANGES IN EQUITY (Un-Audited)
For the Half-year ended 31st December, 2017

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st July, 2016	224,532,000	4,392,110	259,716,820	380,790,698	869,431,628
Net profit after tax	-	-	29,768,758	233,829,346	263,598,104
Dividend for the year 30 June, 2016 (Cash-12.50%)			-	(28,066,500)	(28,066,500)
Dividend for the year 30 June, 2016 (Stock-5%)	33,679,800			(33,679,800)	-
Balance as at 1st July, 2017	258,211,800	4,392,110	289,485,578	552,873,744	1,104,963,232
Total Comprehensive Income/(Loss) for the period ended 30th June, 2017 (Cash-25%)			43,664,977	169,106,546	212,771,523
Dividend for the year 30th June, 2017 (Stock-10%)	25,821,180			(25,821,180)	-
Balance as at 31st December, 2017	284,032,980	4,392,110	333,150,555	631,606,160	1,253,181,805

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Un-Audited)
For the Half-year ended 31st December, 2016

Restated

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2016	224,532,000	4,392,110	245,913,549	358,108,009	832,945,668
Total Comprehensive Income/(Loss)-2016			13,803,271	78,815,689	92,618,960
Dividend for the year, 2015 (Cash-25%)				(56,133,000)	(56,133,000)
Balance as at 1st July, 2016	224,532,000	4,392,110	259,716,820	380,790,698	869,431,628
Total Comprehensive Income/(Loss) for the period ended 31st December, 2016	-	-	-	-	-
Dividend for the half year, 2016 (Cash-12.50%)	-	-	5,030,654	145,156,309	150,186,963
Dividend for the 18th months, 2016 (Stock-15%)	33,679,800	-	-	(28,066,500)	(28,066,500)
Dividend for the 18th months, 2016 (Stock-15%)	33,679,800	-	-	(33,679,800)	-
Balance as at 31st December, 2016	258,211,800	4,392,110	264,747,474	464,200,707	991,552,091



Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
27-Jan-17


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CASH FLOWS (Un-Audited)
For the Half-year ended 31st December, 2017

	Amount in Taka	
	Half-year ended 31.12.2017	Half-year ended 31.12.2016
Cash Flow From Operating Activities:		
Collection from customers & others	2,462,004,364	1,969,125,677
Payment for cost & expenses	(2,207,024,385)	(1,860,196,389)
Miscellaneous Income	150,151	321,540
Cash generated from operations	255,130,130	109,250,828
Income tax paid	(15,678,357)	(18,198,289)
Financial charges	(17,847,994)	(7,923,834)
Net cash provided by operating activities	221,603,779	83,128,705
Cash Flow From Investing Activities:		
Purchase of fixed assets	(256,138,476)	(110,352,781)
Profit from bank deposits & investment	200,647	1,714,512
Net cash used in investing activities	(255,937,829)	(108,638,269)
Cash Flow From Financing Activities:		
Payment of dividend	(44,678,178)	(85,281,550)
Long term finance received/(paid) from bank (net)	117,499,106	84,780,828
Short term finance received/(paid) from bank (net)	(49,320,743)	31,180,398
Net cash flow from financing activities	23,500,185	30,679,676
Increase/(decrease) in cash and cash equivalents	(10,833,865)	5,170,112
Cash and cash equivalents at the opening	197,423,176	169,305,904
Cash and cash equivalents at the closing	186,589,311	174,476,016
Net operating cash flow per share (NOCFPS) (restated-2016)	7.80	2.93


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
27-Jan-17


Managing Director


Chairman

The Ibn Sina Pharmaceutical Industry Ltd.
Selected Notes to the Financial Statements (Un-Audited)

For the Half-year ended 31st December, 2017

Selected Explanatory Notes

01 (a). Basis of Preparation of Financial Statements

These financial Statements have been prepared in line with the accounting policies and methods of computations of the annual financial statements prepared and published for the year ended 30th June, 2017. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

01 (b). Reporting

This half-yearly financial report has been prepared based on Bangladesh Accounting Standard (BAS)-34 "Interim Financial Reporting".

01 (c) Earnings Per Share (EPS)

Earnings per share has been calculated based on number of shares outstanding for the period ended December 31, 2017 and profit for the same period. The number of shares outstanding for the period was 28.403 million. Earnings per share for the corresponding period of 2016 has also been calculated based on 28.403 million shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

01. (d) Restatement of Financial Statement:

Statement of profit or loss and other comprehensive income and statement of changes in equity for the half-year ended on 31st December 2016 has been restated for more compliance with accounting standard by recognising deferred tax on gain/(loss) of marketable securities (available for sales, AFS).

01 (e). Finance charge:

Long term loan balance was Tk.346,995,053.00 and 229,495,947.00 on 31 December 2017 and 30 June 2017 respectively. Due to increase in long term loan finance charge was increased during the reporting period.

01 (f). Net Operating cash flow per share (NOCFPS):

The increase in NOCFPS arose due to the decrease in percentage of payment for trade and other payable and advance income tax in the current reporting period.

01.(g) Subsequent events

No Material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

02. PROPERTY, PLANT AND EQUIPMENT:

Cost/Revaluation

Opening Balance

Addition during the period

Disposal/Adjustment during the period

Accumulated Depreciation

Opening Balance

Charged during the period

Disposal/Adjustment during the period

Written Down Value (WDV)

02.1 Capital work-in-progress

Construction work-in-progress (Building)

Machinery in transit

Amount in Taka	
As at 31.12.2017	As at 30.06.2017
1,606,348,997	1,352,403,379
95,178,990	257,621,978
-	(3,676,360)
1,701,527,987	1,606,348,996
490,016,500	400,679,809
48,187,433	92,504,197
-	(3,167,508)
538,203,933	490,016,498
1,163,324,054	1,116,332,498
35,197,392	26,614,186
152,376,280	-
187,573,672	26,614,186

03. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE):

SI No.	Name of Company Share/Bond	No. of Shares /Bond Held	Face Value Per Share /Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/ Bond as on 31.12.17	Total Market value of shares/ Bond as on 31.12.17	Unrealized Gain/(Loss)
1	Islami Bank Bangladesh Ltd. (IBBL)- in shares	11,013,991	10	32,866,758	2.98	36.60	403,112,071	370,245,313
2	Islami Bank Bangladesh Ltd. (IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	983.00	4,511,970	(78,030)
	Total Taka			37,456,758			407,624,041	370,167,283

a) NET GAIN/(LOSS) ON MARKETABLE SECURITIES (AFS) :

Unrealized Gain/(Loss) Position (Closing)
Deferred tax on gain on marketable securities (AFS)

Amount in Taka	
As at 31.12.2017	As at 30.06.2017

370,167,283	321,650,642
(37,016,728)	(32,165,064)
333,150,555	289,485,578

b) CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES (AFS) :

Unrealized Gain/(Loss) Position (Closing)
Unrealized Gain/(Loss) Position (Opening)

370,167,283	321,650,642
(321,650,642)	(288,574,244)
48,516,641	33,076,398

03.1 INVESTMENT IN ASSOCIATE

Opening balance
Add: Addition during the year
Less: Share of associate profit/(loss)
IBN SINA Consumer Products Ltd.
IBN SINA Consumer Products Ltd. (40% of total share holding)

9,123,147	1,750,000
-	8,000,000
-	(626,853)
9,123,147	9,123,147

04. INVENTORIES:

Raw materials
Packing materials
Work-in-process
Finished goods
Physicians' samples & others

107,686,998	88,563,456
87,378,905	68,253,484
52,752,125	43,928,563
68,415,229	61,978,640
2,573,331	1,470,095
318,806,588	264,194,238

05. ADVANCES, DEPOSITS & PRE-PAYMENTS :

This is recoverable in cash or for value to be received and consists of as follows :

a. Advances against-

Salary
Expenses/Works
Head office
Sales centre rent
Motor cycles - To employees
Income Tax
Others

2,124,248	2,104,138
5,006,154	4,964,944
7,965,000	7,965,000
8,702,625	9,036,110
6,372,605	5,649,951
140,018,375	123,113,838
337,342	247,492
170,526,349	153,081,473

b. Deposits -

Security money

12,694,981 12,727,278

c. Pre-payments -

Value Added Tax (VAT)
Insurance premium

24,320,005	1,009,106
102,998	566,541
24,423,003	1,575,647

(a+b+c)

207,644,333	167,384,398
--------------------	--------------------

	Amount in Taka	
	As at 31.12.2017	As at 30.06.2017
06. CASH & CASH EQUIVALENTS:		
Cash in hand & Bank Balance	180,615,311	191,833,176
Imprest Cash	5,974,000	5,590,000
	186,589,311	197,423,176
07. RETAINED EARNINGS :		
Retained Earnings	552,873,744	380,790,698
Dividend Paid	(90,374,130)	(61,746,300)
Add : Surplus during the period/year	169,106,546	233,829,346
	631,606,160	552,873,744
08. NON-CURRENT LIABILITIES:		
Long Term Finance-Net off current maturity	346,995,053	229,495,947
Retirement Benefit Obligation	36,324,314	13,241,445
	383,319,367	242,737,392
09. DEFERRED TAX ASSET/LIABILITY :		
Deferred Tax Asset/Liability represents deferred tax recognized as asset/liability the movement of which is as below:		
a) Deferred tax liability on net temporary differences:		
Balance as at 1st January	48,348,163	39,478,199
Deferred tax expenses/(income)	4,464,651	8,869,965
	52,812,814	48,348,164
b) Deferred tax liability on change in AFS :		
Balance as at 1st January	32,165,063	28,857,423
Addition/(Less) during the year	4,851,664	3,307,640
	37,016,727	32,165,063
Deferred tax liability at closing balance (a+b)	89,829,541	80,513,227
10. BANK & OTHER FINANCE :		
Short Term Finance	254,295,732	280,421,753
Long Term Finance-Current maturity	23,194,721	46,389,442
	277,490,453	326,811,195
11. ACCOUNTS AND OTHER PAYABLES:		
Payable for Suppliers	170,011,308	141,010,095
Accrued Expenses	97,231,582	85,580,582
Deposits	7,396,660	7,183,446
Other Finance	61,218,963	51,867,542
Income Tax Liability	163,072,838	114,155,184
	498,931,351	399,796,849

12. COST OF GOODS SOLD :

Materials
Factory Overhead
Depreciation

Amount in Taka	
For the half-year (July 01, 2017 to December 31, 2017)	For the half-year (July 01, 2016 to December 31, 2016)
1,187,654,996	953,665,707
238,671,046	187,572,411
41,273,495	36,273,885
<u>1,467,599,537</u>	<u>1,177,512,003</u>

13. ADMINISTRATIVE EXPENSES :

Salary, wages & Allowances
Repairs & Maintenance
Travelling & Conveyance
AGM, Fees and Others
Depreciation
Other Expenses

34,361,577	27,074,896
3,119,974	1,901,371
1,594,732	952,299
1,347,853	601,581
2,603,491	2,564,081
12,031,295	13,272,278
<u>55,058,922</u>	<u>46,366,506</u>

14. SELLING & DISTRIBUTION EXPENSES :

Salary, wages & Allowances
Travelling & Conveyance
Market Survey & Research and Product development
Field personnel expenses
Sample, Literature & Promotional Expenses
Delivery Expenses
Depreciation
Other Expenses


417,665,451	351,610,759
2,462,843	1,829,033
3,919,413	2,345,415
97,687,199	71,426,011
38,867,865	26,594,148
71,732,199	58,210,012
5,310,447	4,607,219
69,028,573	48,913,575
<u>706,673,990</u>	<u>565,536,172</u>


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka
27-Jan-17


Managing Director


Chairman